- Home
- BDRX vs LGVN Comparison
BDRX vs LGVN Comparison
Compare BDRX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- LGVN
- Stock Information
- Founded
- BDRX 2000
- LGVN 2014
- Country
- BDRX United Kingdom
- LGVN United States
- Employees
- BDRX N/A
- LGVN N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- BDRX Health Care
- LGVN Health Care
- Exchange
- BDRX Nasdaq
- LGVN Nasdaq
- Market Cap
- BDRX 2.8M
- LGVN 25.9M
- IPO Year
- BDRX N/A
- LGVN 2021
- Fundamental
- Price
- BDRX $5.98
- LGVN $2.09
- Analyst Decision
- BDRX Strong Buy
- LGVN Strong Buy
- Analyst Count
- BDRX 1
- LGVN 2
- Target Price
- BDRX $200.00
- LGVN $8.00
- AVG Volume (30 Days)
- BDRX 455.7K
- LGVN 393.6K
- Earning Date
- BDRX 10-29-2024
- LGVN 11-08-2024
- Dividend Yield
- BDRX N/A
- LGVN N/A
- EPS Growth
- BDRX N/A
- LGVN N/A
- EPS
- BDRX N/A
- LGVN N/A
- Revenue
- BDRX $104,895.00
- LGVN $1,229,000.00
- Revenue This Year
- BDRX N/A
- LGVN $161.78
- Revenue Next Year
- BDRX N/A
- LGVN $8.62
- P/E Ratio
- BDRX N/A
- LGVN N/A
- Revenue Growth
- BDRX N/A
- LGVN 39.34
- 52 Week Low
- BDRX $4.71
- LGVN $0.77
- 52 Week High
- BDRX $220.25
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- BDRX 42.77
- LGVN 54.70
- Support Level
- BDRX $5.50
- LGVN $1.76
- Resistance Level
- BDRX $10.89
- LGVN $2.26
- Average True Range (ATR)
- BDRX 1.13
- LGVN 0.12
- MACD
- BDRX 0.31
- LGVN 0.05
- Stochastic Oscillator
- BDRX 20.55
- LGVN 66.00
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.